Seqster Launches MyAlzheimer's Patient Registry
Tool targets advanced drug monitoring and safety—and enables access to real-world data.
Seqster PDM, a healthcare technology company, has officially launched
MyAlzheimer's features the ability for patients to grant consent for their data to be used for research purposes, including participation in clinical trials. Caregivers can use the registry to coordinate care and manage medication schedules.
MyAlzheimer's Patient Registry is built on the Seqster operating system, connected to over 5,000 healthcare systems and 150,000 healthcare provider sources.
Reference: Seqster Launches MyAlzheimer's Patient Registry for Advanced Drug Monitoring & Safety, May 9, 2023, San Diego, CA.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025